|
2011 |
Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. |
Roberta Diaz Brinton, Ph.D |
|
2017 |
Sonogashira diversification of unprotected halotryptophans, halotryptophan containing tripeptides; and generation of a new to nature bromo-natural product and its diversification in water |
Christopher Cartmell |
|
2019 |
Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain. |
Tally Largent-Milnes, PhD, Todd Vanderah, PhD |
|
2015 |
Spinal dopaminergic projections control the transition to pathological pain plasticity via a D1/D5-mediated mechanism. |
Patrick W Mantyh |
|
2010 |
Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. |
Tally Largent-Milnes, PhD, Frank Porreca, PhD, Todd Vanderah, PhD |
|
2014 |
Src-mediated post-translational regulation of endoglin stability and function is critical for angiogenesis. |
Nam Lee, Ph.D. |
|
2023 |
Strategies towards safer opioid analgesics-A review of old and upcoming targets. |
John M. Streicher, PhD |
|
2021 |
Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation. |
Thomas P Davis, PhD |
|
2020 |
Structure, Function, and Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders. |
Thomas P Davis, PhD, Jeffrey J. Lochhead, PhD, Patrick T Ronaldson, PhD, FAAPS |
|
2014 |
Structure-activity relationships of non-opioid [des-Arg(7)]-dynorphin A analogues for bradykinin receptors. |
Frank Porreca, PhD |
|
2012 |
Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors. |
Frank Porreca, PhD, Todd Vanderah, PhD |
|
2016 |
Structure-Activity Relationships of [des-Arg(7)]Dynorphin A Analogues at the κ Opioid Receptor. |
Victor Hruby, Ph.D., Tally Largent-Milnes, PhD, Frank Porreca, PhD, John M. Streicher, PhD, Todd Vanderah, PhD |
|
2010 |
Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA. |
Tally Largent-Milnes, PhD, Todd Vanderah, PhD |
|
2017 |
Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists. |
Mohab M. Ibrahim, PhD, MD, Tally Largent-Milnes, PhD, Todd Vanderah, PhD |
|
2017 |
Synergistic interaction of the cannabinoid and death receptor systems - a potential target for future cancer therapies? |
John M. Streicher, PhD |
|
2011 |
Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands. |
Peg Davis, Victor Hruby, Ph.D., Josephine Lai , Ph.D., Frank Porreca, PhD, Todd Vanderah, PhD, Eva Varga, Ph.D. |
|
2018 |
Synthesis and Evaluation of a Novel Bivalent Selective Antagonist for the Mu-Delta Opioid Receptor Heterodimer that Reduces Morphine Withdrawal in Mice. |
John M. Streicher, PhD |
|
2014 |
Synthesis and evaluation of bivalent ligands for binding to the human melanocortin-4 receptor. |
|
|
2022 |
Synthesis of ()()-Tiruchanduramine. |
Christopher Cartmell |
|
2011 |
Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain. |
John M. Streicher, PhD |
|
2017 |
Synthetic analogues of cyanobacterial alkaloid cylindrospermopsin and their toxicological activity. |
Christopher Cartmell |
|
2012 |
Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation. |
Victor Hruby, Ph.D., Tally Largent-Milnes, PhD, Todd Vanderah, PhD, Eva Varga, Ph.D. |
|
2018 |
TAK1 activation of alpha-TAT1 and microtubule hyperacetylation control AKT signaling and cell growth. |
Nam Lee, Ph.D., John M. Streicher, PhD |
|
2022 |
Targeting 5-HT receptors and Kv7 channels in PFC to attenuate chronic neuropathic pain in rats using a spared nerve injury model. |
Tally Largent-Milnes, PhD, Arthur Charles Riegel, Todd Vanderah, PhD |
|
2017 |
Targeting a Potassium Channel/Syntaxin Interaction Ameliorates Cell Death in Ischemic Stroke. |
|
